BioNtech and Pfizer finish dosing first group of subjects in clinical trial
BioNTech and Pfizer finished dosing the first group of subjects for their Phase 1/2 clinical trial for the BNT162 vaccine against Covid-19 and will help China's Fosun Pharma to do the same.
Dow Jones I.A.
43,444.99
04:30 15/10/20
Pfizer Inc.
$24.80
11:09 15/11/24
Pfizer Inc.
$34.31
17:15 22/03/17
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
The German biopharmaceutical group's vaccine utilises so-called mRNA technology which some observers hope may yield a coronavirus more quickly than in the past, perhaps even as soon as 2020.
Dosing for the 12 patient trial in Germany started on 23 April and a similar trial in the US was set to begin as soon as the two companies had received regulatory clearance "which is expected shortly".
The next phase of the trial was set to include 200 healthy subjects with ages ranging from 18 to 55 with a range of doses set to be administered, with the aim of determining the optimal dose for other studies, its safety and its immunogenicity.
In total, four vaccine candidates were set to be studied, with subjects who have a higher risk of a "severe Covid-19 infection to be included in the second part of the study.
During the clinical development stage, BioNTech would supply Pfizer with the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.
BioNTech is collaborating with Fosun Pharma to develop BNT162 in China, where the companies expect to conduct trials.
American Depositary Receipts of Germany-based BioNTech finished 7.46% higher to $49.10 during regular trading hours in New York, alongside a 0.55% advance for Pfizer.